|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
11 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Revenues | |||||
| Collaborative arrangements | |||||
| Total revenues | |||||
| Costs and operating expenses: | |||||
| Contracts with customers and grants | |||||
| Service and Grants | |||||
| Tangible Products | |||||
| Collaborative arrangements | |||||
| Related party transactions | |||||
| Research and development expense | |||||
| Depreciation expense | |||||
| Selling, general and administrative expense | |||||
| Total cost and operating expenses | |||||
| Loss from operations | |||||
| Other income (expense): | |||||
| Change in fair value of derivative warrant liabilities | |||||
| Interest income, net | |||||
| Other income (expense), net | |||||
| Total other income (expense), net | |||||
| Loss before income taxes | |||||
| Income tax expense | |||||
| Loss from equity method investees, net | |||||
| Net loss | |||||
| Other comprehensive loss: | |||||
| Changes in credit risk of fair value instruments | |||||
| Foreign currency translation adjustments | |||||
| Comprehensive loss | |||||
| Unpaid cumulative dividends on preferred stock | |||||
| Net loss allocated to common shareholders | |||||
| Net loss per common share - basic - basic (in usd per share) | |||||
| Total net loss per common share - basic - basic (in usd per share) | |||||
| Net loss per common share - diluted - diluted (in usd per share) | |||||
| Total net loss per common share - diluted - diluted (in usd per share) | |||||
| Weighted-average number of common shares outstanding - basic (in shares) | |||||
| Total weighted-average number of common shares outstanding - basic (in shares) | |||||
| Weighted-average number of common shares outstanding - diluted (in shares) | |||||
| Total weighted-average number of common shares outstanding - diluted (in shares) | |||||
Loading...